查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856586

核醫放射性同位素市場（以放射性藥物分類）－全球預測，2025-2032年

Nuclear Medicine Radioisotopes Market by Radiopharmaceuticals - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，核醫放射性同位素市場規模將達到 364.5 億美元，複合年成長率為 14.96%。

關鍵市場統計數據
基準年 2024 119.4億美元
預計年份：2025年 137.6億美元
預測年份 2032 364.5億美元
複合年成長率 (%) 14.96%

本書權威地介紹了臨床創新、生產技術和監管變革如何重塑核醫放射性同位素生態系統。

受臨床創新、生產技術變革和監管重點調整的驅動，核醫學放射性同位素領域正經歷顯著變化。過去，該領域主要集中於診斷成像和少數由發生器生產的同位素，而如今，它正擴展到精準醫療、一體化診療路徑以及更加分散的生產模式，這些都對傳統的供應鏈提出了挑戰。因此，醫療系統、製造商和監管機構等各方相關人員面臨新的技術和商業性現實，需要製定明智的策略應對措施。

本文簡要回顧了臨床實踐、生產方法和監管預期方面的系統性變化，這些變化正在重新定義該領域。

過去幾年，臨床、供應鏈和法律規範發生了變革性變化，重塑了核子醫學放射性同位素的模式。在臨床上，將診斷影像與標靶放射治療緊密結合的治療模式的快速普及，改變了標準的治療路徑，並對特定的放射性同位素和標記化合物產生了新的需求。同時，分子標靶治療和放射化學的進步拓展了多種藥物的治療適應症，促使它們得到更廣泛的臨床評估和應用。

重點關注2025年美國關稅將如何重塑採購、供應鏈策略和區域製造業優先事項。

2025年，美國推出的關稅政策調整為依賴跨境供應放射性同位素前驅物、發生器、合成模組和特種耗材的相關人員帶來了新的衝擊。這種累積影響體現在籌資策略、供應鏈架構和成本結構等各個面向。依賴進口的企業被迫重新評估其採購策略，許多企業正在加速推動本地生產計劃，或在未受關稅調整影響的市場尋找替代供應商。

詳細的細分分析表明，診斷用PET和SPECT顯像劑及治療方式各自需要不同的技術、臨床和商業策略。

細分分析揭示了診斷和治療性放射性藥物的技術、臨床和商業性動態。診斷性藥物分為PET和SPECT兩類，其中PET藥物如F-18 FDG已成為常規腫瘤成像工具，而F-18 PSMA因其高特異性和相比其他PSMA示踪劑更易於操作，在前列腺癌分期和復發檢測中得到應用。 SPECT藥物由於其成本效益高且γ射線發射同位素廣泛可用，繼續發揮廣泛的臨床作用。治療性藥物包括胜肽受體放射性核素療法，該療法利用生長抑制素受體標靶治療神經內分泌腫瘤，並依賴於具有良好劑量分佈的同位素和配體組合；放射性栓塞療法，該療法將高劑量BETA射線直接輸送到肝臟腫瘤；以及放射免疫療法，該療法將單克隆抗體與細胞毒性同位素相結合，用於靶向全身治療。

重點區域觀點，著重分析美洲、歐洲、中東和非洲以及亞太地區在招募、製造能力和法規環境方面的差異。

美洲、歐洲、中東和非洲以及亞太地區的地理差異導致了顯著不同的應用曲線、監管方式和生產佈局。在美洲，一體化的醫療網路和先進的影像基礎設施支援新型PET示蹤劑和診療一體化藥物的快速臨床應用，同時政策和報銷框架也在不斷完善，以適應高價值放射治療藥物的需求。相較之下，歐洲、中東和非洲地區既有成熟的醫療中心，也面臨物流和監管方面的挑戰，泛歐監管協調工作以及各國為確保同位素供應所做的努力都對生產商和臨床機構的戰略規劃產生了影響。

產業領導者為保障供應鏈、加速臨床應用和提升自身能力所採取的策略性企業因應措施和夥伴關係模式

目前，放射性同位素領域的企業策略強調整合價值鏈、策略夥伴關係以及能力主導的差異化。各公司優先投資於生產技術，例如迴旋加速器網路和自動化合成平台，同時拓展放射化學和臨床開發能力。隨著各機構尋求降低供應風險、加快治療速度並產生支持報銷和更廣泛臨床應用的證據，同位素生產商、受託製造廠商以及臨床服務提供者之間的合作日益普遍。

產業領導者可以實施的可操作建議，以增強供應鏈韌性、加速臨床檢驗並有效實現診療整合創新成果的商業化。

產業領導者應採取一系列協調一致的行動，以增強供應鏈韌性，加快臨床檢驗，並從新的診療整合模式中獲得長期價值。首先，應優先投資於本地生產能力和可行的替代生產途徑，以減少對單一進口的依賴。其次，應促進放射化學家、醫學物理學家和臨床負責人之間的跨學科合作，以完善劑量和安全通訊協定，從而產生可靠的臨床證據，改善患者預後並增強支付方的信心。

採用嚴謹的混合研究途徑，結合專家訪談、技術文獻綜述以及製造和監管流程圖繪製。

本分析所依據的研究採用了一種混合方法，旨在整合技術、臨床和商業觀點。研究人員透過對臨床醫生、放射藥理學家、生產專家和監管顧問進行結構化訪談，收集了主要的定性數據，以了解實踐現狀、未滿足的需求和推廣應用障礙。這些見解與二手技術文獻、同行評審的臨床研究、監管指導文件和公開的臨床試驗註冊資訊進行三角驗證，從而全面了解科學和臨床趨勢。

總結全文，重點在於闡述臨床創新、生產現代化和協作策略之間對於未來成功至關重要的相互作用。

摘要：核醫放射性同位素處於臨床創新、生產現代化和監管完善快速發展的交會點。治療診斷學的興起、迴旋加速器產能的擴張以及對更具韌性的供應鏈的需求，正共同改變放射性藥物的研發、生產和交付方式。透過將技術能力與臨床計畫設計以及積極的監管互動相結合，醫療系統和生產者可以將科學進步轉化為更優質的患者照護。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大鎵-68產能以滿足日益成長的治療診斷學需求
  • 採用鎦-177標靶放射性配體療法進行前列腺癌的先進影像
  • 鉬-99和Technetium-99m放射性同位素供應鏈恢復計劃
  • 利用迴旋加速器生產碘-123以減少核子反應爐的依賴
  • 加速核准新型核醫學同位素的監管協調工作
  • 將人工智慧應用於臨床工作流程中放射性藥物劑量計算的最佳化
  • 開發銅-64標記的PET示蹤劑以提高癌症影像特異性
  • 大型醫療系統在分散式現場RI發電機安裝的投資趨勢
  • 生技公司和核能設施合作推動同位素創新
  • 利用錒-225和鉛-212的α粒子標靶治療在腫瘤學領域日益受到關注。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 核醫放射性同位素市場（以放射性藥物分類）

  • 診斷試劑
    • PET藥物
      • F 18 FDG
      • F 18 PSMA
    • SPECT顯影劑
  • 治療藥物
    • 胜肽受體放射性核種療法
    • 放射性栓塞
    • 放射免疫療法

9. 各地區核子醫學放射性同位素市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第10章 核醫放射性同位素市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第11章 各國核醫放射性同位素市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第12章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • General Electric Company
    • Cardinal Health, Inc.
    • Lantheus Holdings, Inc.
    • Curium SAS
    • Siemens Healthcare GmbH
    • Eckert & Ziegler Strahlen-und Medizintechnik AG
    • Nordion Inc.
    • IRE NV
    • Bracco Imaging SpA
    • Jubilant Radiopharma Limited
Product Code: MRR-742BD51821D7

The Nuclear Medicine Radioisotopes Market is projected to grow by USD 36.45 billion at a CAGR of 14.96% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.94 billion
Estimated Year [2025] USD 13.76 billion
Forecast Year [2032] USD 36.45 billion
CAGR (%) 14.96%

An authoritative introduction explaining how clinical innovation, production technology, and regulatory shifts are reshaping nuclear medicine radioisotope ecosystems

The landscape of nuclear medicine radioisotopes is undergoing a period of substantive change driven by converging clinical innovations, shifts in production technology, and evolving regulatory priorities. Historically centered on diagnostic imaging and a small set of generator-produced isotopes, the field now spans precision therapeutics, integrated diagnostic-therapeutic pathways, and more distributed production models that challenge legacy supply chains. As a result, stakeholders across healthcare systems, manufacturers, and regulators are confronting new technical and commercial realities that require informed strategic responses.

In clinical settings, the expansion of theranostics and targeted radionuclide therapies has redefined disease management for oncology and other specialties, increasing demand for reliable isotopic supply, specialized radiochemistry capabilities, and robust logistics. Concurrently, manufacturing innovations such as expanded cyclotron deployment and alternative Mo-99/Tc-99m production pathways are emerging to mitigate historical bottlenecks. Taken together, these forces are reshaping investment priorities and partnership structures. Therefore, an introduction to this domain must emphasize both the technical specifics of isotope production and the system-level implications for clinical adoption, reimbursement, and cross-industry collaboration.

A concise examination of the systemic transformations in clinical practice, production methods, and regulatory expectations that are redefining the sector

The past several years have revealed transformative shifts that are redefining the nuclear medicine radioisotopes landscape across clinical practice, supply chains, and regulatory frameworks. Clinically, the rapid uptake of theranostic paradigms-where diagnostic imaging tightly couples with targeted radiotherapeutics-has changed standard care pathways and created new demand profiles for specific radioisotopes and labeled compounds. Concurrent advances in molecular targeting and radiochemistry have expanded the therapeutic index for several agents, prompting broader clinical evaluation and adoption.

On the production side, there has been a marked move toward decentralization with greater investment in hospital-based and regional cyclotron capacity, as well as interest in alternative generator and reactor-independent production techniques. These developments are complemented by improvements in automation for synthesis and quality control, which streamline operations and reduce exposure risks. From a regulatory perspective, agencies are refining guidance to accommodate novel radiopharmaceutical manufacturing controls, aseptic processing innovations, and accelerated clinical pathways for high-need indications. Together, these shifts are creating a more resilient yet complex ecosystem that rewards integrated technical capability and agile regulatory engagement.

A focused analysis of how United States tariff measures introduced in 2025 are reshaping procurement, supply chain strategy, and regional manufacturing priorities

In 2025, tariff policy changes instituted by the United States introduced another vector of disruption for stakeholders who depend on cross-border supply of radioisotope precursors, generators, synthesis modules, and specialized consumables. The cumulative impacts are observable across procurement strategies, supply chain architecture, and cost structures. Import-dependent organizations have been prompted to reassess sourcing, with many accelerating local manufacturing projects or seeking alternative suppliers in markets unaffected by tariff adjustments.

Beyond procurement, tariffs have influenced contractual negotiations, inventory management practices, and long-term capital planning. Firms that previously relied on low-cost foreign components are now evaluating vertical integration or strategic partnerships to internalize critical capabilities. At the same time, regulatory and customs complexities have created operational friction that can extend lead times for clinical programs and manufacturing scale-up. As a consequence, industry players are prioritizing supply chain mapping, supplier qualification diversification, and investment in regionalized capacity to mitigate tariff-driven exposure and preserve continuity of care.

Granular segmentation insights revealing how diagnostic PET and SPECT agents and therapeutic modalities each demand distinct technical, clinical, and commercial strategies

Segmentation analysis reveals distinct technical, clinical, and commercial dynamics across diagnostic and therapeutic radiopharmaceuticals. Diagnostic agents split into PET and SPECT categories, with PET agents like F-18 FDG established as routine oncologic imaging tools and F-18 PSMA gaining prominence for prostate cancer staging and recurrence detection because of its superior specificity and logistical handling compared with some alternative PSMA tracers. SPECT agents continue to serve widespread clinical roles where gamma-emitting isotopes remain cost-effective and widely available. Therapeutic agents encompass peptide receptor radionuclide therapy, which leverages somatostatin receptor targeting for neuroendocrine tumors and depends on isotopes and ligands with favorable dosimetry profiles; radioembolization approaches that deliver high-dose beta emitters directly to hepatic tumors; and radioimmunotherapy strategies that combine monoclonal antibodies with cytotoxic isotopes for targeted systemic treatment.

These distinctions carry operational implications for manufacturers and providers. PET workflows require robust radiochemistry, rapid distribution, and regulatory compliance for short-lived isotopes, while therapeutic modalities demand specialized dosimetry, patient selection protocols, and multidisciplinary clinical teams. Consequently, organizations involved in radiopharmaceutical development must align laboratory capabilities, distribution networks, and clinical partnerships to address the unique requirements of each segment and to translate scientific advances into meaningful patient outcomes.

Key regional perspectives showing how adoption, manufacturing capacity, and regulatory environments vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Geographic variation drives meaningful differences in adoption curves, regulatory approaches, and manufacturing footprints across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, integrated healthcare networks and advanced imaging infrastructure support rapid clinical adoption of novel PET tracers and theranostic agents, while policy and reimbursement frameworks are evolving to accommodate high-value radiotherapeutics. By contrast, Europe, the Middle East & Africa present a heterogeneous landscape where well-established centers of excellence coexist with regions that face logistical and regulatory hurdles; pan-European regulatory harmonization efforts and national initiatives to secure isotope supply influence strategic planning for producers and clinical sites.

In the Asia-Pacific region, rapid investment in cyclotron capacity, growing clinical trial activity, and increasing domestic manufacturing capabilities are notable trends. Several markets in the region are focusing on expanding local production to reduce import dependency and to address rising clinical demand. Across all regions, differences in reimbursement models, hospital infrastructure, and regulatory timelines necessitate tailored commercialization strategies and local partnerships to achieve sustainable access and scale.

Strategic corporate responses and partnership models that industry leaders are deploying to secure supply chains, accelerate clinical adoption, and differentiate through capabilities

Corporate strategies in the radioisotope domain now emphasize integrated value chains, strategic partnerships, and capability-led differentiation. Firms are prioritizing investments in production technologies, such as cyclotron networks and automated synthesis platforms, while also expanding capabilities in radiochemistry and clinical development. Collaboration between isotope producers, contract development and manufacturing organizations, and clinical providers is increasingly prevalent as organizations seek to de-risk supply, accelerate time to clinic, and build evidence that supports reimbursement and broader clinical adoption.

In addition, companies are diversifying route-to-market approaches by licensing proprietary ligands, forming co-development agreements for theranostic pairs, and pursuing regional manufacturing alliances. Intellectual property management, quality systems harmonization, and regulatory engagement remain central to competitive positioning. Collectively, these strategies reflect a shift from single-product development toward end-to-end solutions that marry isotope supply security with clinical utility and commercial scalability.

Actionable recommendations that industry leaders can implement to strengthen supply resilience, accelerate clinical validation, and commercialize theranostic innovations effectively

Industry leaders should pursue a coordinated set of actions that strengthen supply resilience, accelerate clinical validation, and position organizations to capture long-term value from emerging theranostic paradigms. First, prioritize investment in regional production capacity and validated alternative production pathways to reduce dependency on single-source imports. Second, cultivate multidisciplinary collaborations between radiochemists, medical physicists, and clinical trialists to generate robust clinical evidence and to refine dosing and safety protocols that improve patient outcomes and payer confidence.

Furthermore, organizations should engage proactively with regulators to shape pragmatic pathways for quality assurance, sterility testing, and lot release that reflect the technical realities of short-lived isotopes. Operationally, integrating automation and digital quality controls can reduce turnaround times and enhance reproducibility. Finally, commercial strategies must focus on building payer relationships and demonstrating real-world value through outcomes and health economic evidence, while also developing flexible distribution and inventory models that accommodate the logistical constraints of radiopharmaceuticals.

A rigorous mixed-methods research approach integrating primary expert interviews, technical literature synthesis, and production and regulatory process mapping

The research underpinning this analysis employed a mixed-methods approach designed to integrate technical, clinical, and commercial perspectives. Primary qualitative data were collected through structured interviews with clinicians, radiopharmacists, manufacturing specialists, and regulatory advisors to capture operational realities, unmet needs, and adoption barriers. These insights were triangulated with secondary technical literature, peer-reviewed clinical studies, regulatory guidance documents, and publicly available clinical trial registries to ensure a comprehensive understanding of scientific and clinical trends.

Analytical steps included a systematic mapping of production technologies, a review of manufacturing process controls relevant to radiopharmaceuticals, and an assessment of logistics and cold-chain considerations specific to short-lived isotopes. The methodology emphasized reproducibility by documenting data sources, interview protocols, and analytical assumptions, and by conducting sensitivity checks on qualitative findings. Where applicable, patent landscapes and regulatory filings were examined to validate strategic positioning and to identify potential technology inflection points.

A conclusive synthesis emphasizing the critical interplay of clinical innovation, production modernization, and collaborative strategies for future success

In summary, nuclear medicine radioisotopes occupy a fast-evolving junction of clinical innovation, manufacturing modernization, and regulatory refinement. The rise of theranostics, expansion of cyclotron capacity, and the need for more resilient supply chains are collectively altering how radiopharmaceuticals are developed, produced, and delivered. Healthcare systems and manufacturers that align technical capabilities with clinical program design and proactive regulatory engagement will be best positioned to translate scientific advances into improved patient care.

Moving forward, success will depend on cross-sector collaboration, transparent supply chain strategies, and evidence generation that demonstrates clinical and economic value. By embracing integrated approaches that combine secure isotope production, automated manufacturing processes, and targeted clinical development, stakeholders can mitigate operational risk while accelerating adoption of next-generation diagnostic and therapeutic radiopharmaceuticals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of gallium-68 production capacity to meet growing theranostics demand
  • 5.2. Adoption of lutetium-177 targeted radioligand therapies for advanced prostate cancer imaging
  • 5.3. Supply chain resilience initiatives for molybdenum-99 and technetium-99m radioisotopes
  • 5.4. Emerging cyclotron-based production of iodine-123 to reduce reactor dependence
  • 5.5. Regulatory harmonization efforts for fast-track approval of novel nuclear medicine isotopes
  • 5.6. Integration of artificial intelligence for optimized radiopharmaceutical dose calculation in clinical workflows
  • 5.7. Development of copper-64 labeled PET tracers for enhanced cancer imaging specificity
  • 5.8. Investment trends in decentralized on-site radioisotope generator installations by major health systems
  • 5.9. Collaborative partnerships between biotech companies and nuclear facilities driving isotope innovation
  • 5.10. Growth of alpha-emitting targeted therapies using actinium-225 and lead-212 in oncology applications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine Radioisotopes Market, by Radiopharmaceuticals

  • 8.1. Diagnostic Agents
    • 8.1.1. PET Agents
      • 8.1.1.1. F 18 Fdg
      • 8.1.1.2. F 18 Psma
    • 8.1.2. SPECT Agents
  • 8.2. Therapeutic Agents
    • 8.2.1. Peptide Receptor Radionuclide Therapy
    • 8.2.2. Radioembolization
    • 8.2.3. Radioimmunotherapy

9. Nuclear Medicine Radioisotopes Market, by Region

  • 9.1. Americas
    • 9.1.1. North America
    • 9.1.2. Latin America
  • 9.2. Europe, Middle East & Africa
    • 9.2.1. Europe
    • 9.2.2. Middle East
    • 9.2.3. Africa
  • 9.3. Asia-Pacific

10. Nuclear Medicine Radioisotopes Market, by Group

  • 10.1. ASEAN
  • 10.2. GCC
  • 10.3. European Union
  • 10.4. BRICS
  • 10.5. G7
  • 10.6. NATO

11. Nuclear Medicine Radioisotopes Market, by Country

  • 11.1. United States
  • 11.2. Canada
  • 11.3. Mexico
  • 11.4. Brazil
  • 11.5. United Kingdom
  • 11.6. Germany
  • 11.7. France
  • 11.8. Russia
  • 11.9. Italy
  • 11.10. Spain
  • 11.11. China
  • 11.12. India
  • 11.13. Japan
  • 11.14. Australia
  • 11.15. South Korea

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Analysis
    • 12.3.1. General Electric Company
    • 12.3.2. Cardinal Health, Inc.
    • 12.3.3. Lantheus Holdings, Inc.
    • 12.3.4. Curium SAS
    • 12.3.5. Siemens Healthcare GmbH
    • 12.3.6. Eckert & Ziegler Strahlen- und Medizintechnik AG
    • 12.3.7. Nordion Inc.
    • 12.3.8. IRE NV
    • 12.3.9. Bracco Imaging S.p.A.
    • 12.3.10. Jubilant Radiopharma Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NUCLEAR MEDICINE RADIOISOTOPES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. NUCLEAR MEDICINE RADIOISOTOPES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NUCLEAR MEDICINE RADIOISOTOPES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 FDG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY F 18 PSMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PEPTIDE RECEPTOR RADIONUCLIDE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOEMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOIMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 71. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 98. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 113. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 115. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 122. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 124. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 126. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 128. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 129. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 132. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 133. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 134. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 135. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 136. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 137. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 138. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 154. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 155. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 156. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 157. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 158. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 159. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 160. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 161. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 164. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 165. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 166. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 167. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 168. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 169. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 170. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 181. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 184. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 185. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 186. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 191. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 194. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 195. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 196. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 197. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 198. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 199. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 200. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 201. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 204. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 205. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 206. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 207. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 208. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 209. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 210. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 219. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 221. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 223. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 225. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 227. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 229. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 231. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 233. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 235. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 237. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 239. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 241. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 243. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 255. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 257. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 259. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 261. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 263. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 265. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 267. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 269. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 270. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 271. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 272. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 273. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 275. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 277. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 278. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 279. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 280. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 281. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 282. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 283. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 284. ITALY NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 285. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 287. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 289. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 291. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 293. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2024 (USD MILLION)
  • TABLE 294. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RADIOPHARMACEUTICALS, 2025-2032 (USD MILLION)
  • TABLE 295. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 296. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 297. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2018-2024 (USD MILLION)
  • TABLE 298. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET AGENTS, 2025-2032 (USD MILLION)
  • TABLE 299. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 300. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC AGENTS, 2025-